Skip to main content
. 2009 Nov 10;4(11):e7766. doi: 10.1371/journal.pone.0007766

Figure 2. The time and amount of IL-2 required for promoting CD8+ T-cell activation.

Figure 2

(A) Recombinant human IL-2 (rhIL-2, 5 ng/mL) was administrated at indicated time following CD8+ T-cell stimulation by anti-CD3/CD28 antibodies. Following 96 hours, cell viability was measured by MTT assay at absorbance of 570 nm (▪). The cells were incubated with rhIL-2 alone as control (□). (B) In the presence (○) or absence (▪) of rhIL-2 in priming stage, naive CD8+ T cells from 2C TCR transgenic mice were stimulated with specific peptide, QL9 in titrations for 96 hours, followed by MTT assay. (C) In the presence (•) or absence (▪) of rhIL-2 in priming stage, naïve B6 CD8+ T cells were stimulated by anti-CD3 in titrated concentrations for 96 hours, followed by MTT assay. (D) rhIL-2 in titrated concentrations, 5, 0.5 or 0.05 ng/mL was administered to the CD8+ T cells at 0 (▪), 12 (•) and 24 (▴) hours after stimulation by anti-CD3/CD28 antibodies. The cells were incubated with rhIL-2 alone as controls. Following 96 hours, cell viability was measured by MTT assay. The data represent three independent experiments. *, significantly statistical difference by student t-test, p<0.05.